Chinese Journal of Pharmaceuticals
|
2023, 54(6): 950-956
• Pharmaceutical Management & Information •
Analysis and Enlightenment of cGMP Warning Letters Sent by FDA to Chinese Pharmaceutical Manufacturers
Full
Linlin CAO
1, Yating QIAN
2, Qingsong ZHANG
2, Haijian LI
1, Haoxiang XIAO
1, Wei LIU
2, *
Affiliations
- 1.Henan Provincial Drug Evaluation and Inspection Center, Zhengzhou 450000
- 2.School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001
Published: 2023-06-10
doi: 10.16522/j.cnki.cjph.2023.06.017
Outline
曹琳琳, 钱雅婷, 张青松, 李海剑, 肖皓祥, 刘伟.
FDA发给中国药品生产企业cGMP警告信的分析与启示.
中国医药工业杂志,
2023
, 54
(6)
: 950
-956
.
DOI: 10.16522/j.cnki.cjph.2023.06.017
Linlin CAO, Yating QIAN, Qingsong ZHANG, Haijian LI, Haoxiang XIAO, Wei LIU.
Analysis and Enlightenment of cGMP Warning Letters Sent by FDA to Chinese Pharmaceutical Manufacturers[J].
Chinese Journal of Pharmaceuticals,
2023
, 54
(6)
: 950
-956
.
DOI: 10.16522/j.cnki.cjph.2023.06.017
Year 2023 volume 54 Issue 6
34
12
Cite this Article
BibTeX
Article Info
doi: 10.16522/j.cnki.cjph.2023.06.017
- Receive Date:2023-03-14
- Online Date:2026-11-19
- Published:2023-06-10